| 21.05 08:58 | dpa-AFX: Smiths Group Reports Q3 Organic Revenue Growth Of 7.7% |
| 21.05 08:22 | dpa-AFX: *SMITHS GROUP 9-MONTH ORGANIC REVENUE GROWTH OF 5.2% |
| 21.05 08:04 | dpa-AFX: *SMITHS GROUP CONTINUES TO EXPECT FY24 ORGANIC REVENUE GROWTH OF 4%-6% |
| 21.05 08:03 | dpa-AFX: *SMITHS GROUP Q3 ORGANIC REVENUE GROWTH UP 7.7% |
| 11.04 07:57 | dpa-AFX: *HSBC HEBT SMITHS GROUP AUF 'BUY' (HOLD) - ZIEL 2000 (1875) PENCE |
| 11.04 07:57 | dpa-AFX: *HSBC RAISES SMITHS GROUP TO 'BUY' (HOLD) - PRICE TARGET 2000 (1875) PENCE |
| 26.03 08:49 | dpa-AFX: Smith Group To Start First Tranche Of GBP 100 Mln Of Share Repurchase |
| 26.03 08:48 | dpa-AFX: *GOLDMAN RAISES SMITHS GROUP PRICE TARGET TO 2250 (2220) PENCE - 'BUY' |
| 26.03 08:40 | dpa-AFX: Smiths Group Names Roland Carter CEO With Immediate Effect, Succeeding Paul Keel |
| 26.03 08:36 | dpa-AFX: Smiths Group H1 Headline Operating Profit Rises; Organic Revenue Growth At 3.9% |
| 26.03 08:25 | dpa-AFX: *SMITHS TO COMMENCE FIRST TRANCHE OF PROGRAMME TO PURCHASE ORDINARY SHARES OF UP TO GBP 50 MLN |
| 26.03 08:18 | dpa-AFX: *SMITHS GROUP APPOINTS ROLAND CARTER AS GROUP'S CEO AND AS A DIRECTOR |
| 26.03 08:05 | dpa-AFX: *SMITHS GROUP H1 HEADLINE BASIC EPS 48.7P VS 46.6P PRIOR YEAR |
| 12.03 06:26 | dpa-AFX: *GOLDMAN CUTS SMITHS GROUP PRICE TARGET TO 2220 (2240) PENCE - 'BUY' |
| 01.03 08:17 | dpa-AFX: Smiths Group Confirms Sale Of 830K Shares In ICU Medical |
| 01.03 08:05 | dpa-AFX: *SMITHS GROUP SELLS 830K SHARES IN ICU MEDICAL |
| 30.01 18:20 | dpa-AFX: *JEFFERIES RAISES SMITHS GROUP PRICE TARGET TO 2180 (2040) PENCE - 'BUY' |
| 08.12 05:59 | dpa-AFX: *JPMORGAN CUTS SMITHS GROUP PRICE TARGET TO 1910 (1980) PENCE - 'OVERWEIGHT' |
| 16.11 08:58 | dpa-AFX: *GOLDMAN RAISES SMITHS GROUP PRICE TARGET TO 2220 (2180) PENCE - 'BUY' |
| 16.11 08:39 | dpa-AFX: Smiths Group Q1 Organic Revenue Up 3.5% |
|
|
